ScripJohnson & Johnson has sought to carve out a leading position in the treatment of multiple myeloma, and presentations at the American Society of Clinical Oncology and European Hematology Associatio
ScripGilead Sciences has obtained US approval for its HIV-1 capsid inhibitor, lenacapavir, as a twice-yearly subcutaneous injection to prevent HIV infection – an endorsement that should secure the product
ScripMerck & Co’s PD-1 inhibitor for multiple cancer indications Keytruda (pembrolizumab) comfortably retained its number one spot as the drug generating the highest global revenues in the first quarte
ScripBristol Myers Squibb’s CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) may see an expansion in its addressable population with positive Phase II data in marginal zone lymphoma (MZL). The drugma